


PHARMACEUTICAL 2021

KEMPHARM INC Rank 292 of 409





PHARMACEUTICAL 2021

KEMPHARM INC Rank 292 of 409

The relative strengths and weaknesses of KEMPHARM INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KEMPHARM INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 149% points. The greatest weakness of KEMPHARM INC is the variable Assets, Current, reducing the Economic Capital Ratio by 153% points.

The company's Economic Capital Ratio, given in the ranking table, is -281%, being 74% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	8,382
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,536
Liabilities, Non-Current	1,732
Other Assets	1,788
Other Compr. Net Income	0
Other Expenses	2,099
Other Liabilities	68,353
Other Net Income	-7,185
Property and Equipment	1,039
Research and Development	8,843
Revenues	13,288
Selling, General and Administrative Expense	7,921

Output Variable	Value in 1000 USD
Assets	11,209
Liabilities	77,621
Expenses	18,863
Stockholders Equity	-66,412
Net Income	-12,760
Comprehensive Net Income	-12,760
Economic Capital Ratio	-281%